Chemed CORP 8-K filings

Chemed Corporation reported strong second-quarter 2026 financial results, with revenue up 8.8% and EPS soaring 43.7%, primarily driven by outperformance in its VITAS Healthcare segment, leading to an increase in full-year guidance.

Chemed Corporation's annual meeting saw the election of directors and ratification of independent accountants, but a non-binding vote on executive compensation failed to gain majority approval.

Chemed Corporation reported Q1 2026 results with strong VITAS growth, leading to an upward revision of full-year earnings guidance.

Chemed Corporation has successfully renewed its $450 million senior secured credit facilities, enhancing its financial flexibility with an expansion option.

Chemed Corporation reported a 9% drop in GAAP diluted EPS for Q4 2025, with its Roto-Rooter segment experiencing a significant revenue and EBITDA decline, while VITAS showed modest revenue growth.

Chemed Corporation reported a 3.1% revenue increase to $624.9 million for Q3 2025, but GAAP diluted EPS fell 10.8% to $4.46, driven by margin declines in both VITAS Healthcare and Roto-Rooter segments.

Chemed Corporation announced a significant decline in second-quarter earnings and a downward revision to its full-year 2025 guidance, primarily due to increased Medicare Cap billing limitations at its VITAS segment, alongside the resignation of VITAS's CEO.

Chemed Corporation announced it anticipates lower second quarter earnings and is reducing its full year 2025 guidance due to a projected Medicare Cap revenue limitation for its VITAS subsidiary and unexpected weakness in Roto-Rooter's residential business.

Chemed Corporation successfully held its annual meeting on May 19, 2025, electing directors and approving proposals related to stock incentives, auditor ratification, and executive compensation.

Chemed Corporation announces a 9.8% increase in revenue to $646.9 million for the first quarter of 2025, driven by strong performance in its VITAS Healthcare segment.

Chemed Corporation announces its fourth-quarter 2024 financial results, highlighting revenue growth in its VITAS Healthcare segment but a decline in its Roto-Rooter segment.

Chemed Corporation's third-quarter results show strong growth in its VITAS hospice segment, which was partially offset by a decline in Roto-Rooter's plumbing and drain cleaning business.

Chemed Corporation's second quarter results show significant growth in its VITAS Healthcare segment, offsetting a decline in Roto-Rooter revenue.

Chemed Corporation successfully held its annual meeting on May 20, 2024, electing all nominated directors and approving the ratification of independent accountants and executive compensation program.

Chemed Corporation's first quarter 2024 results show significant growth in the VITAS segment, offsetting a decline in Roto-Rooter revenue.

Chemed Corporation's subsidiary, VITAS Healthcare, has completed the acquisition of hospice operations and an assisted living facility from Covenant Health for $85 million.

Chemed Corporation's VITAS Healthcare is set to acquire hospice assets and an assisted living facility from Covenant Care for $85 million, expanding its reach in Florida and Alabama.

Chemed Corporation's Q4 2023 results show significant growth in the VITAS segment, offsetting a slight revenue decrease in Roto-Rooter.

Chemed Corporation granted 6,424 performance share units to David P. Williams, who is transitioning to an advisory role, with vesting dependent on the company's total shareholder return over the next three years.